Pfizer Plays Up Its In-house Potential, Avoids M&A Talk
Executive Summary
Pfizer execs say they are focused on commercial execution and pipeline development to drive growth. No viable buyer has emerged for the consumer business, CEO Read said.
You may also be interested in...
Pfizer’s Hopes For Ibrance In Adjuvant Breast Cancer Fall With PALLAS
Ibrance (palbociclib) is unlikely to succeed in the adjuvant trial, the data safety monitoring board concluded. Pfizer has another adjuvant trial due later this year.
Pfizer Remains Flexible On Consumer Health In Restructuring
The adage "the more things change, the more they stay the same" may come to mind for Pfizer's consumer business: it will be a standalone division as part of a restructuring that takes effect in January but it's still for sale.
Pfizer Remains Flexible On Consumer Health In Restructuring
The adage "the more things change, the more they stay the same" may come to mind for Pfizer's consumer business: it will be a standalone division as part of a restructuring that takes effect in January but it's still for sale.